Literature DB >> 24576605

Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction.

J Michael Elliott1, Mark Ultsch2, Joshua Lee1, Raymond Tong1, Kentaro Takeda1, Christoph Spiess3, Charles Eigenbrot3, Justin M Scheer4.   

Abstract

Bispecific antibody and antibody-like molecules are of wide interest as potential therapeutics that can recognize two distinct targets. Among the variety of ways such molecules have been engineered is by creating "knob" and "hole" heterodimerization sites in the CH3 domains of two antibody heavy chains. The molecules produced in this manner maintain their biological activities while differing very little from the native human IgG sequence. To better understand the knob-into-hole interface, the molecular mechanism of heterodimerization, and to engineer Fc domains that could improve the assembly and purity of heterodimeric reaction products, we sought crystal structures of aglycosylated heterodimeric and homodimeric "knob" and "hole" Fc fragments derived from bacterial expression. The structure of the knob-into-hole Fc was determined at 2.64 Å. Except for the sites of mutation, the structure is very similar to that of the native human IgG1 Fc, consistent with a heterodimer interaction kinetic K(D) of <1 nM. Homodimers of the "knob" and "hole" mutants were also obtained, and their X-ray structures were determined at resolutions 2.5 Å and 2.1 Å, respectively. Both kinds of homodimers adopt a head-to-tail quaternary structure and thus do not contain direct knob/knob or hole/hole CH3 interactions. The head-to-tail arrangement was disfavored by adding site-directed mutations at F241 and F243 in the CH2 domains, leading to increases in both rate and efficiency of bispecific (heterodimer) assembly.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  CH3 domain; antibody structure; bispecific antibody; heterodimer interface; hydrophobic interface

Mesh:

Substances:

Year:  2014        PMID: 24576605     DOI: 10.1016/j.jmb.2014.02.015

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  15 in total

1.  MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.

Authors:  Jessica B Casaletto; Melissa L Geddie; Adnan O Abu-Yousif; Kristina Masson; Aaron Fulgham; Antoine Boudot; Tim Maiwald; Jeffrey D Kearns; Neeraj Kohli; Stephen Su; Maja Razlog; Andreas Raue; Ashish Kalra; Maria Håkansson; Derek T Logan; Martin Welin; Shrikanta Chattopadhyay; Brian D Harms; Ulrik B Nielsen; Birgit Schoeberl; Alexey A Lugovskoy; Gavin MacBeath
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-21       Impact factor: 11.205

2.  Synergistic Neutralization of Pertussis Toxin by a Bispecific Antibody In Vitro and In Vivo.

Authors:  Ellen K Wagner; Xianzhe Wang; Andre Bui; Jennifer A Maynard
Journal:  Clin Vaccine Immunol       Date:  2016-11-04

3.  Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity.

Authors:  Jing Li; Changhua Zhou; Bin Dong; Hong Zhong; Siqi Chen; Qing Li; Zhong Wang
Journal:  Cancer Biol Ther       Date:  2016-09-19       Impact factor: 4.742

4.  Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.

Authors:  K J Froning; A Leaver-Fay; X Wu; S Phan; L Gao; F Huang; A Pustilnik; M Bacica; K Houlihan; Q Chai; J R Fitchett; J Hendle; B Kuhlman; S J Demarest
Journal:  Protein Sci       Date:  2017-07-31       Impact factor: 6.725

5.  Computationally Designed Bispecific Antibodies using Negative State Repertoires.

Authors:  Andrew Leaver-Fay; Karen J Froning; Shane Atwell; Hector Aldaz; Anna Pustilnik; Frances Lu; Flora Huang; Richard Yuan; Saleema Hassanali; Aaron K Chamberlain; Jonathan R Fitchett; Stephen J Demarest; Brian Kuhlman
Journal:  Structure       Date:  2016-03-17       Impact factor: 5.006

6.  Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.

Authors:  Yiren Xu; John Lee; Cuong Tran; Tyler H Heibeck; Willie D Wang; Junhao Yang; Ryan L Stafford; Alexander R Steiner; Aaron K Sato; Trevor J Hallam; Gang Yin
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 7.  Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins.

Authors:  Ji-Hee Ha; Jung-Eun Kim; Yong-Sung Kim
Journal:  Front Immunol       Date:  2016-10-06       Impact factor: 7.561

Review 8.  Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.

Authors:  Hongyan Liu; Abhishek Saxena; Sachdev S Sidhu; Donghui Wu
Journal:  Front Immunol       Date:  2017-01-26       Impact factor: 7.561

9.  Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening.

Authors:  Hye-Ji Choi; Ye-Jin Kim; Dong-Ki Choi; Yong-Sung Kim
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

10.  Structural basis of a novel heterodimeric Fc for bispecific antibody production.

Authors:  Hudie Wei; Haiyan Cai; Yuhao Jin; Pilin Wang; Qingqing Zhang; Yihui Lin; Weixiao Wang; Jinke Cheng; Naiyan Zeng; Ting Xu; Aiwu Zhou
Journal:  Oncotarget       Date:  2017-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.